Ana Del Pozo‐rodríguez - Nanotechnology

Author Information

Ana del Pozo-Rodríguez is a prominent researcher affiliated with the Pharmacokinetic, Nanotechnology & Gene Therapy Group (PharmaNanoGene) at the Faculty of Pharmacy, Centro de investigación Lascaray ikergunea, University of the Basque Country UPV/EHU in Vitoria-Gasteiz, Spain. Her work primarily focuses on the fields of nanotechnology and gene therapy, with a special emphasis on the development of nanomedicines and gene delivery systems.

Research Contributions

Ana del Pozo-Rodríguez has made significant contributions to the field of nanotechnology and gene therapy. Her research includes the development of mRNA-based nanomedicinal products for addressing corneal inflammation, non-viral gene therapy for Fabry disease, and the creation of educational materials for teaching nanotechnology. Her work often explores innovative strategies for treating corneal conditions and leveraging gene therapy for medical advancements. Notably, her research spans from practical applications in medical treatments to educational innovations in the university context.

Aliases

Ana del Pozo-Rodríguez is also known by several aliases, including A Del Pozo-rodríguez, A. Del Pozo-rodríguez, and Ana Del Pozo-rodríguez.

Publication and Citation Metrics

Metric	Value
Citation Count	1450
h-index	20
Paper Count	33

Publications:

mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation

DOI: 10.3390/pharmaceutics13091472

Year: 2021

α-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice

DOI: 10.3390/pharmaceutics13060771

Year: 2021

INQUIRY / RESEARCH -BASED LEARNING (IBL/RBL) FOR THE DEVELOPMENT OF THE FINAL DEGREE PROJECT IN PHARMACY DURING THE SUPERVISED PRACTICUM AND FOCUSED ON PROFESSIONAL PHARMACY SERVICES

DOI: 10.21125/iceri.2021.0432

Year: 2021

Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives

DOI: 10.3390/nano10020364

Year: 2020

Topical Administration of SLN-Based Gene Therapy for the Treatment of Corneal Inflammation by De Novo IL-10 Production

DOI: 10.3390/pharmaceutics12060584

Year: 2020

SYNERGIES TO CREATE EDUCATIONAL INNOVATION IN THE UNIVERSITY CONTEXT: ELABORATION OF AUDIO-VISUAL AND INTERACTIVE INSTRUCTIVE MATERIALS FOR THE TEACHING NANOTECHNOLOGY

DOI: 10.21125/iceri.2019.1325

Year: 2019

MMP-9 Downregulation with Lipid Nanoparticles for Inhibiting Corneal Neovascularization by Gene Silencing

DOI: 10.3390/nano9040631

Year: 2019

Gene Therapy.

DOI: 10.1007/10_2019_109

Year: 2019

Targeting corneal inflammation by gene therapy: Emerging strategies for keratitis

DOI: 10.1016/j.exer.2018.07.006

Year: 2018

Hiccups in Parkinson’s disease: an analysis of cases reported in the European pharmacovigilance database and a review of the literature

DOI: 10.1007/s00228-017-2275-6

Year: 2017

What is the Future of Nanocoated IOLs in Ophthalmology?

What are Common Solvents Used?

Why is Nanomechanical Sensing Important?

What is the Impact on Minimally Invasive Surgery Training?

What are the Objectives of the NIA?

What Are the Applications of 3D Nanoprinting?

What Challenges Exist in Using Electrical Fields at the Nanoscale?

Can Quantum Decoherence Be Controlled or Mitigated?

What Information Can EXAFS Provide About Nanomaterials?

What are Nanoscale Actuators?

Partnered Content Networks

Relevant Topics